Summary of potential predictors of survival
| Potential predictor . | No. of patients (no. of deaths) . | Median survival, y (95% CI) . | P* . |
|---|---|---|---|
| Total | 113 (78) | — | — |
| Patient characteristics at initial presentation, no. of extranodal lesions† | |||
| 0 or 1 | 69 (47) | 1.6 (0.9, 2.6) | .004 |
| 2 or more | 29 (23) | 0.4 (0.2, 2.6) | — |
| Patient characteristics at brain relapse | |||
| Age | .006 | ||
| Under 60 years of age | 43 (26) | 2.9 (1.2, 6.3) | — |
| 60 years or older | 70 (52) | 0.9 (0.5, 1.9) | — |
| ECOG performance status‡ | .033 | ||
| 0, 1, 2 | 51 (30) | 2.2 (1.2, 3.3) | — |
| 3, 4 | 44 (35) | 0.7 (0.4, 2.2) | — |
| Cerebrospinal fluid cytology§ | .048 | ||
| Positive | 11 (8) | 0.5 (0.1, 9.7) | — |
| Negative | 56 (31) | 2.2 (1.6, 3.5) | — |
| Front-line treatment of brain relapse‖ | |||
| Treatment includes methotrexate | .008 | ||
| Yes | 71 (45) | 2.6 (1.0, 3.5) | — |
| No | 42 (33) | 0.6 (0.4, 1.9) | — |
| Treatment includes chemotherapy | .019 | ||
| Yes | 78 (51) | 2.2 (0.9, 3.3) | — |
| No | 35 (27) | 0.6 (0.4, 1.9) | — |
| Treatment includes WBRT | .20 | ||
| Yes | 60 (47) | 0.9 (0.5, 1.9) | — |
| No | 53 (31) | 2.6 (0.9, 3.3) | — |
| Treatment includes methotrexate and WBRT | .16 | ||
| Yes | 22 (17) | 1.7 (0.9, 7.0) | — |
| No | 91 (61) | 1.2 (0.6, 2.4) | — |
| Potential predictor . | No. of patients (no. of deaths) . | Median survival, y (95% CI) . | P* . |
|---|---|---|---|
| Total | 113 (78) | — | — |
| Patient characteristics at initial presentation, no. of extranodal lesions† | |||
| 0 or 1 | 69 (47) | 1.6 (0.9, 2.6) | .004 |
| 2 or more | 29 (23) | 0.4 (0.2, 2.6) | — |
| Patient characteristics at brain relapse | |||
| Age | .006 | ||
| Under 60 years of age | 43 (26) | 2.9 (1.2, 6.3) | — |
| 60 years or older | 70 (52) | 0.9 (0.5, 1.9) | — |
| ECOG performance status‡ | .033 | ||
| 0, 1, 2 | 51 (30) | 2.2 (1.2, 3.3) | — |
| 3, 4 | 44 (35) | 0.7 (0.4, 2.2) | — |
| Cerebrospinal fluid cytology§ | .048 | ||
| Positive | 11 (8) | 0.5 (0.1, 9.7) | — |
| Negative | 56 (31) | 2.2 (1.6, 3.5) | — |
| Front-line treatment of brain relapse‖ | |||
| Treatment includes methotrexate | .008 | ||
| Yes | 71 (45) | 2.6 (1.0, 3.5) | — |
| No | 42 (33) | 0.6 (0.4, 1.9) | — |
| Treatment includes chemotherapy | .019 | ||
| Yes | 78 (51) | 2.2 (0.9, 3.3) | — |
| No | 35 (27) | 0.6 (0.4, 1.9) | — |
| Treatment includes WBRT | .20 | ||
| Yes | 60 (47) | 0.9 (0.5, 1.9) | — |
| No | 53 (31) | 2.6 (0.9, 3.3) | — |
| Treatment includes methotrexate and WBRT | .16 | ||
| Yes | 22 (17) | 1.7 (0.9, 7.0) | — |
| No | 91 (61) | 1.2 (0.6, 2.4) | — |
CI indicates confidence interval; and —, not applicable.
P value compares survival across strata for each predictor.
Number of extranodal lesions was not reported in 15 patients.
Performance status was not reported in 18 patients.
Cerebrospinal fluid cytology was not reported in 46 patients.
One patient had brain surgery only and was excluded from the analysis of treatment characteristics.